1 August 2018Americas

Amneal obtains non-infringement finding in Sensipar case

Generic drug maker Amneal has secured a finding of non-infringement in a Hatch-Waxman case over kidney disease drug Sensipar (cinacalcet hydrochloride).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen takes on Emcure over Sensipar generic

10 September 2018 Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.

Court grants order to resolve Amgen v FDA paediatric dispute

6 June 2017 A district court has granted a stipulated order to the US Food and Drug Administration and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar.

Amgen sues Apotex over Sensipar generic

14 October 2016 Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar tablets.

More on this story

Amgen takes on Emcure over Sensipar generic

10 September 2018 Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.

Court grants order to resolve Amgen v FDA paediatric dispute

6 June 2017 A district court has granted a stipulated order to the US Food and Drug Administration and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar.

Amgen sues Apotex over Sensipar generic

14 October 2016 Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar tablets.

More on this story

Amgen takes on Emcure over Sensipar generic

10 September 2018 Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.

Court grants order to resolve Amgen v FDA paediatric dispute

6 June 2017 A district court has granted a stipulated order to the US Food and Drug Administration and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar.

Amgen sues Apotex over Sensipar generic

14 October 2016 Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar tablets.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

Bayer appoints new head of IP

WATCH: Policy direction—where are we now?